FDA approves Biosense's ablation catheter:
This article was originally published in Clinica
Executive Summary
The FDA has approved Biosense Webster's Navi-Star temperature ablation catheter for sale in the US. The device is designed for use with the company's Carto electrophysiological mapping system. Together they provide the only three-dimensional mapping technology on the market that combines real-time catheter location and radiofrequency (RF) temperature ablation in a single procedure, claims Biosense. The catheter integrates reproducible pinpoint location and accurate catheter positioning for safe and precise RF ablation procedures, says Diamond Bar, California-based Biosense, a Johnson & Johnson company.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.